Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Placebo-subtracted mean weight loss up to 8.4% at Day 36

19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination

Well-tolerated with no safety signals

Read more at globenewswire.com